Marshall Wace’s Achillion Pharmaceuticals ACHN Stock Holding History

Marshall Wace’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-37,495	Closed	-$100K	–	2026
2019 Q2	$100K	Buy	+37,495	New	+$111K	﹤0.01%	1273
2016 Q3	–	Sell	-540,611	Closed	-$4.22M	–	1213
2016 Q2	$4.22M	Sell	540,611 -361,591	-40%	-$3.1M	0.04%	426
2016 Q1	$6.96M	Sell	902,202 -68,660	-7%	-$503K	0.07%	271
2015 Q4	$10.5M	Buy	970,862 +261,007	+37%	+$2.37M	0.1%	216
2015 Q3	$4.91M	Buy	709,855 +311,229	+78%	+$2.54M	0.06%	299
2015 Q2	$3.53M	Buy	398,626 +239,586	+151%	+$2.27M	0.05%	357
2015 Q1	$1.57M	Buy	159,040 +77,056	+94%	+$962K	0.02%	506
2014 Q4	$1M	Buy	+81,984	New	+$1M	0.01%	566
2014 Q3	–	Sell	-30,829	Closed	-$233K	–	1115
2014 Q2	$233K	Buy	+30,829	New	+$123K	﹤0.01%	815

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Marshall Wace's ACHN Position: Q3 2019 in Review

Marshall Wace sold out of Achillion Pharmaceuticals (ACHN) in Q3 2019, closing a stake of 37,495 shares — an estimated $100K sold.

Marshall Wace first reported a position in ACHN in Q2 2014 and held it in 9 quarters. The position peaked at $10.5M in Q4 2015. 122 funds tracked by Wall St. Rank hold ACHN as of Q3 2019.

Marshall Wace reported no remaining Achillion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Marshall Wace sold 37,495 Achillion Pharmaceuticals shares in Q3 2019, an estimated $100K.
Marshall Wace first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 9 quarters.
Marshall Wace's Achillion Pharmaceuticals position peaked at $10.5M in Q4 2015.
122 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2019.

Based on Marshall Wace's 13F filing for Q3 2019, filed 14 Nov 2019.